RxDoctor Payments Data

Carlos Tavera, MD

Internal Medicine · Grand Rapids, MINPI 1942277348

Payments from drug & device makers

$1,412in general payments, 2019–2025

Across 20 payments — averaging $70.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$487
  • Novartis$217
  • E.r. Squibb & Sons, L.L.C.$209
  • Novo Nordisk$207
  • CSL Behring$125
  • Boehringer Ingelheim$113
  • plus $54 from 1 others

What the payments were for

  • Food & beverage$1,412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,412 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$17,956
Medicare patients
93
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$85,942
JardianceEmpagliflozin42$60,720
TrulicityDulaglutide43$58,457
EliquisApixaban33$38,211
MounjaroTirzepatide18$29,161
FarxigaDapagliflozin Propanediol15$14,198
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,382
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$5,566
Atorvastatin Calcium217$3,061
Novolog FlexpenInsulin Aspart13$2,548
Losartan Potassium133$1,908
Omeprazole98$1,536
Metformin Hcl124$1,370
Levothyroxine Sodium81$1,350
Amlodipine Besylate143$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$487$87,61961 claims
Novo NordiskOzempic$207$85,94264 claims
Boehringer IngelheimJardiance$113$60,72042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →